ISRIB A15 (CAS: 1628478-12-5) Powder or Capsules

Price range: $310.00 through $1,850.00

High-affinity eIF2B activator and next-generation Integrated Stress Response (ISR) inhibitor. Synthesized as an advanced analog of ISRIB with superior oral bioavailability, enhanced blood–brain-barrier penetration (~8-hour plasma half-life), and an EC50 of approximately 0.8 nM (6.25× more potent than parent ISRIB). Formulated for laboratory investigations evaluating traumatic brain injury, age-related neurodegeneration, translational control, and synaptic plasticity. Purity verified at ≥98% via HPLC and NMR.

Description

Product Overview

ISRIB A15 (also designated as ISR-IN-2) is a next-generation structural analog of ISRIB developed to resolve solubility and pharmacokinetic constraints while delivering enhanced potency. Acting directly at the intersection of cellular stress and translational control, A15 is a potent molecular stabilizer of the eukaryotic translation initiation factor 2B (eIF2B) decameric complex.

Under cellular stress conditions, phosphorylation of eIF2α acts as a competitive inhibitor of eIF2B, causing global suppression of mRNA translation and halting protein synthesis. ISRIB A15 binds with sub-nanomolar affinity at the β/δ subunit interface of eIF2B, functionally acting as a molecular staple that locks the complex into its active enzymatic conformation regardless of eIF2α phosphorylation status.

Key Research Applications

  • Traumatic Brain Injury & Concussion Recovery: Evaluated in animal models of concussive trauma and CTE, where sustained ISR activation halts dendritic spine remodeling and working memory. Research demonstrates post-injury administration can reset elevated ISR signaling and restore cognitive performance.
  • Age-Related Cognitive Decline & Neurodegeneration: Chronically elevated eIF2α phosphorylation in aging brain tissue impairs long-term potentiation (LTP). A15 enables research into restoring protein supply chains required for memory consolidation across models of Alzheimer’s, ALS, and frontotemporal dementia.
  • eIF2B Structural Biology & Leukodystrophies: Investigated as a rescue compound in cellular models of Vanishing White Matter Disease (VWMD) and for cryo-EM characterization of eIF2B decamer assembly.
  • Synaptic Plasticity & Memory Consolidation: Facilitates sustained synthesis of plasticity-associated proteins (BDNF, CaMKII, Arc) during persistent cellular stress without triggering pancreatic toxicity associated with broader PERK inhibition.

Chemical & Technical Specifications

  • Chemical Name: N,N’-((1r,4r)-cyclohexane-1,4-diyl)bis(2-(3,4-dichlorophenoxy)acetamide)
  • Synonyms: ISRIB A15, ISR-IN-2, ISRIB Analog 15
  • Molecular Formula: C₂₂H₂₂Cl₄N₂O₄
  • Molecular Weight: 520.23 g/mol
  • Primary Target: eIF2B Activator (EC50 ≈ 0.8 nM, 6.25× more potent than ISRIB)
  • Purity: ≥98.0% (HPLC)
  • Form: White to off-white crystalline solid / powder
  • Solubility: Soluble in DMSO
  • Storage: 2°C to 8°C. For in vitro laboratory research use only.

Additional information

Format

Powder, Capsules

Quantity

100mg, 500mg, 1g, 2g, 5g, 10g

Disclaimer: Supplied strictly as a high-purity chemical reagent for laboratory research and development use only. Not for human or animal consumption.

Our Products